Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis

Song Yao, Yali Zhang, Li Tang, Janise M. Roh, Cecile A. Laurent, Chi Chen Hong, Theresa Hahn, Joan C. Lo, Christine B. Ambrosone, Lawrence H. Kushi, Marilyn L. Kwan

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Purpose: The majority of breast cancer patients receive endocrine therapy, including aromatase inhibitors known to cause increased bone resorption. Bone-related biomarkers at the time of breast cancer diagnosis may predict future risk of osteoporosis and fracture after endocrine therapy. Methods: In a large population of 2,401 female breast cancer patients who later underwent endocrine therapy, we measured two bone remodeling biomarkers, TRAP5b and BAP, and two bone regulating biomarkers, RANKL and OPG, in serum samples collected at the time of breast cancer diagnosis. We analyzed these biomarkers and their ratios with patients’ demographic, lifestyle, clinical tumor characteristics, as well as bone health history. Results: The presence of bone metastases, prior bisphosphonate (BP) treatment, and blood collection after chemotherapy had a significant impact on biomarker levels. After excluding these cases and controlling for blood collection time, several factors, including age, race/ethnicity, body mass index, physical activity, alcohol consumption, smoking, and hormonal replacement therapy, were significantly associated with bone biomarkers, while vitamin D or calcium supplements and tumor characteristics were not. When prior BP users were included in, recent history of osteoporosis and fracture was also associated. Conclusions: Our findings support further investigation of these biomarkers with bone health outcomes after endocrine therapy initiation in women with breast cancer.

Original languageEnglish (US)
Pages (from-to)1-13
Number of pages13
JournalBreast Cancer Research and Treatment
DOIs
StateAccepted/In press - Dec 3 2016
Externally publishedYes

Fingerprint

Bone Remodeling
Biomarkers
Breast Neoplasms
Bone and Bones
Diphosphonates
Osteoporosis
Therapeutics
Aromatase Inhibitors
Age Factors
Health
Bone Resorption
Vitamin D
Alcohol Drinking
Life Style
Neoplasms
Body Mass Index
Smoking
Demography
Exercise
Neoplasm Metastasis

Keywords

  • Aromatase inhibitor
  • Biomarker
  • Bone
  • Breast cancer
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Yao, S., Zhang, Y., Tang, L., Roh, J. M., Laurent, C. A., Hong, C. C., ... Kwan, M. L. (Accepted/In press). Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis. Breast Cancer Research and Treatment, 1-13. https://doi.org/10.1007/s10549-016-4068-5

Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis. / Yao, Song; Zhang, Yali; Tang, Li; Roh, Janise M.; Laurent, Cecile A.; Hong, Chi Chen; Hahn, Theresa; Lo, Joan C.; Ambrosone, Christine B.; Kushi, Lawrence H.; Kwan, Marilyn L.

In: Breast Cancer Research and Treatment, 03.12.2016, p. 1-13.

Research output: Contribution to journalArticle

Yao, S, Zhang, Y, Tang, L, Roh, JM, Laurent, CA, Hong, CC, Hahn, T, Lo, JC, Ambrosone, CB, Kushi, LH & Kwan, ML 2016, 'Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis', Breast Cancer Research and Treatment, pp. 1-13. https://doi.org/10.1007/s10549-016-4068-5
Yao, Song ; Zhang, Yali ; Tang, Li ; Roh, Janise M. ; Laurent, Cecile A. ; Hong, Chi Chen ; Hahn, Theresa ; Lo, Joan C. ; Ambrosone, Christine B. ; Kushi, Lawrence H. ; Kwan, Marilyn L. / Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis. In: Breast Cancer Research and Treatment. 2016 ; pp. 1-13.
@article{598e09cd70964124b824d1aff8b7fabf,
title = "Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis",
abstract = "Purpose: The majority of breast cancer patients receive endocrine therapy, including aromatase inhibitors known to cause increased bone resorption. Bone-related biomarkers at the time of breast cancer diagnosis may predict future risk of osteoporosis and fracture after endocrine therapy. Methods: In a large population of 2,401 female breast cancer patients who later underwent endocrine therapy, we measured two bone remodeling biomarkers, TRAP5b and BAP, and two bone regulating biomarkers, RANKL and OPG, in serum samples collected at the time of breast cancer diagnosis. We analyzed these biomarkers and their ratios with patients’ demographic, lifestyle, clinical tumor characteristics, as well as bone health history. Results: The presence of bone metastases, prior bisphosphonate (BP) treatment, and blood collection after chemotherapy had a significant impact on biomarker levels. After excluding these cases and controlling for blood collection time, several factors, including age, race/ethnicity, body mass index, physical activity, alcohol consumption, smoking, and hormonal replacement therapy, were significantly associated with bone biomarkers, while vitamin D or calcium supplements and tumor characteristics were not. When prior BP users were included in, recent history of osteoporosis and fracture was also associated. Conclusions: Our findings support further investigation of these biomarkers with bone health outcomes after endocrine therapy initiation in women with breast cancer.",
keywords = "Aromatase inhibitor, Biomarker, Bone, Breast cancer, Tamoxifen",
author = "Song Yao and Yali Zhang and Li Tang and Roh, {Janise M.} and Laurent, {Cecile A.} and Hong, {Chi Chen} and Theresa Hahn and Lo, {Joan C.} and Ambrosone, {Christine B.} and Kushi, {Lawrence H.} and Kwan, {Marilyn L.}",
year = "2016",
month = "12",
day = "3",
doi = "10.1007/s10549-016-4068-5",
language = "English (US)",
pages = "1--13",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",

}

TY - JOUR

T1 - Bone remodeling and regulating biomarkers in women at the time of breast cancer diagnosis

AU - Yao, Song

AU - Zhang, Yali

AU - Tang, Li

AU - Roh, Janise M.

AU - Laurent, Cecile A.

AU - Hong, Chi Chen

AU - Hahn, Theresa

AU - Lo, Joan C.

AU - Ambrosone, Christine B.

AU - Kushi, Lawrence H.

AU - Kwan, Marilyn L.

PY - 2016/12/3

Y1 - 2016/12/3

N2 - Purpose: The majority of breast cancer patients receive endocrine therapy, including aromatase inhibitors known to cause increased bone resorption. Bone-related biomarkers at the time of breast cancer diagnosis may predict future risk of osteoporosis and fracture after endocrine therapy. Methods: In a large population of 2,401 female breast cancer patients who later underwent endocrine therapy, we measured two bone remodeling biomarkers, TRAP5b and BAP, and two bone regulating biomarkers, RANKL and OPG, in serum samples collected at the time of breast cancer diagnosis. We analyzed these biomarkers and their ratios with patients’ demographic, lifestyle, clinical tumor characteristics, as well as bone health history. Results: The presence of bone metastases, prior bisphosphonate (BP) treatment, and blood collection after chemotherapy had a significant impact on biomarker levels. After excluding these cases and controlling for blood collection time, several factors, including age, race/ethnicity, body mass index, physical activity, alcohol consumption, smoking, and hormonal replacement therapy, were significantly associated with bone biomarkers, while vitamin D or calcium supplements and tumor characteristics were not. When prior BP users were included in, recent history of osteoporosis and fracture was also associated. Conclusions: Our findings support further investigation of these biomarkers with bone health outcomes after endocrine therapy initiation in women with breast cancer.

AB - Purpose: The majority of breast cancer patients receive endocrine therapy, including aromatase inhibitors known to cause increased bone resorption. Bone-related biomarkers at the time of breast cancer diagnosis may predict future risk of osteoporosis and fracture after endocrine therapy. Methods: In a large population of 2,401 female breast cancer patients who later underwent endocrine therapy, we measured two bone remodeling biomarkers, TRAP5b and BAP, and two bone regulating biomarkers, RANKL and OPG, in serum samples collected at the time of breast cancer diagnosis. We analyzed these biomarkers and their ratios with patients’ demographic, lifestyle, clinical tumor characteristics, as well as bone health history. Results: The presence of bone metastases, prior bisphosphonate (BP) treatment, and blood collection after chemotherapy had a significant impact on biomarker levels. After excluding these cases and controlling for blood collection time, several factors, including age, race/ethnicity, body mass index, physical activity, alcohol consumption, smoking, and hormonal replacement therapy, were significantly associated with bone biomarkers, while vitamin D or calcium supplements and tumor characteristics were not. When prior BP users were included in, recent history of osteoporosis and fracture was also associated. Conclusions: Our findings support further investigation of these biomarkers with bone health outcomes after endocrine therapy initiation in women with breast cancer.

KW - Aromatase inhibitor

KW - Biomarker

KW - Bone

KW - Breast cancer

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=85002959406&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85002959406&partnerID=8YFLogxK

U2 - 10.1007/s10549-016-4068-5

DO - 10.1007/s10549-016-4068-5

M3 - Article

SP - 1

EP - 13

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

ER -